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Optimal management of high-grade obstructive carotid
artery disease at the time of open heart surgery (OHS) has
never been addressed in a randomized clinical trial. Data
suggest that the combined approach of carotid endarterec-
tomy (CEA) and OHS leads to a higher risk of procedural
stroke (1–3), and, therefore, staged carotid revascularization
by CEA or carotid artery stenting (CAS) is often performed
before OHS. Does the staged approach lead to an over-
all reduction in the rate of major adverse cardiovascular
events (MACE ¼ death, myocardial infarction, and stroke)
for patients with concomitant coronary and cerebrovascular
disease? The current study reported in this issue of the
Journal by Shishehbor et al. (4) would suggest that this is
true, but only for staged CAS followed by OHS.See page 1948Randomized, controlled trials have demonstrated the
superiority of CEA over optimal medical therapy for
reducing the future risk of stroke in patients with high-grade
carotid artery stenosis (5–8). In patients determined to be at
either standard or high risk of perioperative complications
during CEA, randomized trials have also shown the non-
inferiority of CAS versus CEA in reducing the risk of future
MACE (9–11). However, there has been criticism leveled at
these data meticulously acquired over the past 2 decades.
First, optimal medical therapy has evolved since the com-
pletion of the pivotal randomized trials comparing medical
therapy with CEA. It has been posited that if such trials
were performed today with contemporary antiplatelet, lipid-
lowering, and antihypertensive therapy, the beneﬁts of CEA
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this paper to disclose.stroke in symptomatic patients at 2 to 3 years [6,7,12,13]
and 5% to 6% vs. 11% to 12% death/stroke in asymptom-
atic patients at 5 years [5,8]) might not be as compelling,
especially in asymptomatic patients. However, as all the
patients in the current study required OHS, they were at
a higher risk of stroke than the patients in the medical
therapy versus CEA trials. Second, in the CAS versus CEA
trials, myocardial infarction was included as an endpoint.
Cumulative data show that the 30-day risk of myocardial
infarction is higher with CEA, whereas the risk of minor,
nondebilitating cerebrovascular accidents is higher with CAS
(11). Major stroke rates at short and longer term follow-up
are comparable with both strategies (10,11). Numerous
registries limited to patients at high surgical risk during CEA
also support an acceptably low rate of MACE after CAS for
both symptomatic and asymptomatic patients (14–16).
Importantly, the adverse prognosis after perioperative
myocardial infarction for noncardiac and vascular surgery is
well recognized and of great relevance in discussing the
optimal treatment of obstructive carotid disease (17,18).
The study by Shishehbor et al. (4) is unique in that it
addresses a cohort of patients with a single high-risk feature
during carotid revascularization (i.e., pre-OHS). This is
a retrospective analysis of 350 patients treated at the
Cleveland Clinic from 1997 to 2009 who presented with
combined high-grade coronary and carotid artery disease
and met indications for revascularization of both vascular
territories. The majority of patients (81%) had asymptomatic
carotid disease (the absence of an ipsilateral transient
ischemic attack or stroke in the previous 6 months) and
underwent coronary artery bypass graft surgery with/without
concomitant valve surgery (92%). The study cohort was
divided into 3 groups: combined CEA-OHS (n ¼ 195),
staged CEA followed by OHS (n ¼ 45), and staged CAS
followed by OHS (n ¼ 110). Staged CEA was shortly fol-
lowed by OHS (median interval, 14 days), whereas a 3- to 4-
week interval of dual antiplatelet therapy was usually
completed before OHS in the staged CAS-OHS group
(median interval, 47 days).
Using all-cause mortality, stroke, and myocardial infarc-
tion as a combined primary endpoint, the results of the study
show that staged CAS followed by OHS results in a lower
risk of MACE compared with the staged CEA-OHS
approach (adjusted hazard ratio [HR]: 0.49, 95% conﬁ-
dence interval [CI]: 0.24 to 1.0; p ¼ 0.06) and similar risk of
MACE compared with the combined CEA-OHS approach
(adjusted HR: 0.99, 95% CI: 0.61 to 1.62; p ¼ 0.97) at the
early (1 year) hazard phase. Mortality rates were comparable
in all 3 treatment strategies in the early hazard phase,
whereas a higher stroke rate was observed in the combined
CEA-OHS group and a higher myocardial infarction rate in
the staged CEA-OHS group. The late hazard phase (beyond
1 year) favored the staged CAS-OHS group (adjusted HR:
0.33, 95% CI: 0.15 to 0.77; p ¼ 0.01 compared with staged
CEA-OHS and HR: 0.35, 95% CI: 0.18 to 0.70; p ¼ 0.003
compared with combined CEA-OHS groups). This late
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1958difference was primarily driven by higher all-cause mortality
in the staged and combined CEA groups beyond 1 year after
the index OHS.
The investigators of the current study performed 3 very
important analyses to strengthen their reported ﬁndings.
They derived a propensity score and performed a baseline
risk-adjusted comparison of the 3 groups for the composite
endpoint and mortality. This propensity-adjusted model was
conﬁrmed by performing a propensity-matched analysis
in a large subgroup. Second, they provided a median follow-
up of 3.7 years, extending the results of their ﬁndings
beyond the perioperative period. Third, they systematically
analyzed each individual patient included in the analysis to
capture all adverse clinical events during the follow-up
period including all intertreatment events as a part of their
MACE endpoint.
Although a propensity-adjusted analysis was performed to
account for the baseline differences between the 3 groups,
nearly universal neurological monitoring of CAS patients
during the time frame of this study likely resulted in a bias
favoring CEA with respect to stroke as an endpoint. Add-
itionally, embolic protection devices were only used in 82%
of the CAS procedures in this study. Nevertheless, the
staged CAS-OHS group had a similar 30-day stroke rate
compared with the staged CEA-OHS group and a lower
rate than the combined CEA-OHS group.
Although a recent analysis from the CARE registry
revealed similar in-hospital and 30-day MACE rates with
either CAS or CEA before urgent open heart surgery (19),
the registry did not separate staged CEA and combined
CEA-OHS, and longer term follow-up was not available. A
smaller previous study suggested that CAS before OHS
results in superior outcomes compared with combined
CEA-OHS at 30 days (3). However, the study did not in-
clude intertreatment events, and the results of the current
study refute those ﬁndings at the early hazard phase.
The systematic collection of all intertreatment events
for each individual patient evaluated is a particular
strength of this study. A higher incidence of myocardial
infarction was observed in the staged CEA-OHS group,
whereas the combined CEA-OHS group had the highest
incidence of stroke. These data are consistent with
previous studies showing a higher incidence of myocardial
infarction after CEA in standard- and high-risk patients
(8–10). Notably, even in standard-risk carotid disease
patients, increased 4-year mortality associated with ca-
rotid revascularization–related myocardial infarction has
been reported from CREST (Carotid Revascularization
Endarterectomy vs Stenting Trial) (20).
As with most retrospective studies, criticisms of this study
include the lack of randomization and inherent treatment bias
associated with the 3 strategies. Additionally, the role of
adjunctivemedical therapy as the sole treatment strategy before
OHS was not evaluated. Conceivably, this is also a strength of
the study in that it reﬂects actual practice patterns. As most
cardiac surgeons are loathe to proceed with OHS in thepresence of high-grade carotid disease, a 3-way randomized
trial with medical therapy as an arm would have enrollment
bias (asymptomatic moderate disease patients randomized
only). Furthermore, as patients with high-grade carotid disease
included in the current study met clinical criteria for carotid
revascularization, the question of medical therapy as a long-
term treatment strategy for these patients is irrelevant.
This study provides clarity in the management of patients
with carotid and coronary disease requiring OHS. For
patients presenting with an acute coronary syndrome re-
quiring urgent coronary revascularization in whom waiting 3
to 4 weeks is not safe, combined CEA-OHS is the optimum
revascularization strategy, although it is associated with
higher neurological ischemic events. However, for patients
with a stable or an accelerating anginal syndrome who can
wait 3 to 4 weeks to complete dual antiplatelet therapy after
carotid stenting, staged CAS followed by OHS leads to
superior early and long-term outcomes. Staged CEA fol-
lowed by OHS is associated with an increased short-term
(interstage myocardial infarction) and long-term (mortality)
hazard and should be avoided. As the majority of patients in
this study were undergoing isolated coronary revasculariza-
tion during OHS, the data should be interpreted with
caution in patients with isolated valvular or concomitant
coronary and valvular heart disease requiring OHS.
This leads to the ﬁnal issue confronted by practicing
physicians. Despite a wealth of data acquired over 20 years of
careful clinical research, CAS only remains available for
symptomatic high-risk patients in the United States. In
standard-risk or asymptomatic high-risk patients, enroll-
ment in post-marketing registries is required. As patients
requiring carotid revascularization before OHS are recog-
nized as a high-risk cohort, the symptomatic status of the
patient should not be a factor for reimbursement in this
cohort. The present study suggests that the currently
acceptable option of CEA before OHS actually endangers
the patient, leading to the highest ischemic event rate, both
early and late after OHS. These patients should either
undergo combined CEA-OHS or be offered the option of
CAS before OHS based on medical criteria, not reim-
bursement issues.
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